Heavy Bleeding In Nursing Essay

A multidisciplinary approach is taken to provide safe, effective treatment while minimizing patient risk. Patients are treated due to chronic pelvic pain issues, with or without subfertility considerations. The FNP can prescribe NSAIDS to address pelvic pain issues. Steroid hormone derived medications like oral contraceptives are also prescribed to suppress growth and activity of the endometrial implants and provide cycle control. If this approach is ineffective, gonadotropin-releasing hormone (GnRH) agonists like Leuprolide can be prescribed for up to a year to significantly decrease estrogen levels, thereby decreasing chronic pelvic pain (Solnik, 2015). However, the FNP can also counsel hormone therapy to reduce menopausal effects on bone mineral density and serotonin reuptake inhibitors (SSRIs) to address vasomotor symptoms like hot flashes Another effective hormonal pharmaceutical therapy includes progesterone like medroxyprogesterone acetate and anti-progestin. As well, in advanced disease the FNP may elect to implant the levonorgestrel intrauterine device (IUD) as a progestin derived alternative (Schenken,

Recent studies have suggested that bioidentical hormone replacement therapy (BHRT) might prove to be an effective treatment

The condition Polycystic ovary syndrome(PCOS) is the most common of endocrine disruptions within women of reproductive ages. The disorder does affect as much as 10% of women within this reproductive lifecycle. The clinical and biochemical features of the condition are diverse and are as follows: fertility disruption, overweight/obesity, irregularities in menstruation (frequent, absent, sporadic) insulin resistance/type 2 diabetes, and increased risk of cardiovascular disease (Jeanes &Hart &Smith & Barr, 2009). The exact aetiology of Polycystic ovary syndrome (PCOS) is unknown but does involve both environmental influencers and genetic factors. In summery Polycystic ovary syndrome (PCOS) is a common endocrine condition associated with metabolic dysfunction, infertility, and hyperandrogenism. Treatment for PCOS includes diet and lifestyle changes in order to promote a healthy body mass index (BMI) and further reduce hyperinsulinaemia (a symptom of the condition). Medications such as metformin/Glucophage might be utilized for management of the presenting symptoms. PCOS symptoms at present-day can only be managed and no cure for Polycystic ovary syndrome available. (Jeanes &Hart &Smith & Barr, 2009).

This paper will discuss a chronic endocrine disorder known as polycystic ovarian syndrome also known as PCOS. “This syndrome is common among women who are

“It is imperative that there be an open discussion overtly identifying the issues and discussing them without prejudice” (Johnson 2012 p. 265) Under specific circumstances, families may have the right to use medical advances to improve their overall quality of life however, this slippery slope must be controlled by the leaders in the medical community. Doctors and committee members need to be aware of both sides of each issue and combine the priorities they have as medical professionals, with the related socio political priorities. Additionally, doctors should have experience administering and monitoring such treatment prior to accepting patients for Growth-Attenuation Treatment. FDA regulations and guidelines, for use of estrogen, would need to be established and an oversight committee would be formed to ensure the process remains ethically sound. “In order to act as an exemplary follower, you’ll need to practice exercising, independent, critical thought and by becoming actively engaged in organizational affairs.” (Johnson, 2012 p. 293) Furthermore, the medical professionals would need to publicly declare that caution should be exercised regarding the treatment’s use, due to a lack of existing data. This would alert the public to the importance of their being educated consumers and it might help to better align the expectations of all involved, with the range of possible outcomes. It is premature to determine the ethical nature of Growth-Attenuation Treatment. “...Relational Leadership...emphasize that leaders need to be concerned about ethical processes as well as ethical products…” (Johnson, 2012, p. 265) There exist three main issues in the processes of this treatment as it stands today. The prescribing of this medication for off shelf use requires doctors to guess the appropriate dosage for their desired

• Unexpected bleeding such as unusual bleeding from the gums, nose bleeding frequently, and periods that are heavier than

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive aged women, with a prevalence of 16.6-18% according to the 2003 Rotterdam criteria (1-3). Though PCOS is extremely common, up to 70% of women with the syndrome are undiagnosed (3). The PCOS diagnosis is one of ovarian dysfunction and hyperandrogenism, and as such has important implications for reproductive health (see Table 1; NIH, 2012). However, in addition to these reproductive criteria – which tend to manifest as hirsutism, infertility, and pregnancy complications – PCOS is marked by

The patient will first need to be treated with recombinant human growth hormone (Ross, Cao, Feuillan, Kowal, Chipman, & Cutler, 2011); the patient may not be average height, but treatment does significantly increase the final adult height of the patient. Treatment for Ovarian failure is much more difficult and offers unique challenges because the timing and necessary dosage may fluctuate depending on the patient (Ros, Balasch, Mullol, & Castelo-Branco, 2013). Lifelong medical care is extremely important, and patients do not need to cease treatment as they grow beyond adolescence so medical professionals can continue to prevent or treat health problems that could be fatal. Lack of quality medical treatment as an adult can reverse positive goals attained during pediatric care and could possibly result in the death of the patient (Davies,

Polycystic ovarian syndrome (PCOS) is the most prevalent endocrine abnormality of reproductive-aged women, occurring between 10 and 21% (March et al., 2010). Due to its complexity, PCOS is associated with a spectrum of symptoms, including amenorrhea, anovulation, hirsutism, acne, and obesity. All of which are subjective and do not allow for a definitive diagnosis. Long term complications, such as infertility, insulin resistance, dyslipidemia, depression, and anxiety require an early diagnosis; but establishing a comprehensive diagnostic criterion has been difficult (Teede et al., 2011). Historically, Stein and Leventhal first identified PCOS in 1935 when they associated it with hirsutism, chronic anovulation, obesity, and bilateral ovarian

Most cases are mild, and you may need treatment only if you have surgery, tooth extraction, or any injury or trauma. The medicines are used to increase the amount of von Willebrand factor that is released into the bloodstream, prevent the breakdown of blood clots, and control heavy menstrual period bleeding in women. (Pollak, MD, 2014).

It is common for women to experience heavy menstrual bleeding at some point in their life. These periods can be painful making it difficult for one to function in their daily work. A good percentage of women who experience this situation also known as menorrhagia goes on to develop anemia.

Age, hormone levels, sexual maturation, previous medical history, and patient preference are the basis for hormone replacement therapy. Uterine development was based on two measurements, the uterine cross sectional area (UXA) and the maturity of the uterus (Kim et al, 2016). All patients were given daily doses of medications including estradiol valerate (0.5-2.0 mg doses) and 10 mg medroxyprogesterone acetate for 12 days on each month. The dosage was varied on an individual basis (Kim et al,

It is extremely important to notify health care providers if any of the following signs and symptoms of bleeding occur: easy bruising of the skin, petechiae, blood in urine, black tarry stools, nosebleeds, bleeding from the gums, increase in vaginal bleeding, and new onset of painful joints. (Williams, L. S., & Hopper, P. D. (2015, p. 573-574).

Many women who have postpartum hemorrhage have no risk factors. Which is why prevention of postpartum hemorrhage should not be ignored regardless of whether the patient is considered high risk or not. It is unfortunate to acknowledge the increasingly high percentage of maternal deaths related to postpartum hemorrhage considering that more than half of the cases are essentially preventable. The leading cause of maternal death is plainly put as hemorrhage. There are many ways that hemorrhage can be reduced, techniques including active management, identifying hemorrhage at its earliest onset and trigger, and reducing the rates of

This is a silent disease because many people don’t even know they have it. But, when someone who is suffering from VWD starts bleeding, they will undergo severe bleeding. Just because an individual might not present with symptoms, doesn’t mean they won’t suffer from the severe bleeding consequences. This lack of knowledge is due to the fact that the symptoms of VMD are so mild. This factor can either be missing or it can just be defective. VWF is known as a clotting protein (https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Von-Willebrand-Disease).